Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Lung Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Liver Failure 1HRD Cancer 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Drug-Related Side Effects and Adverse Reactions 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Radiosurgery 9Temozolomide 8Magnetic Resonance Spectroscopy 5pembrolizumab 4Specimen Handling 4Nivolumab 4Bevacizumab 4Receptors, Interleukin-8B 3Memantine 3trastuzumab deruxtecan 2abemaciclib 2Watchful Waiting 2Surveys and Questionnaires 2Radiotherapy 2Radiation 2Mental Status and Dementia Tests 2Ipilimumab 2Biopsy 2sotorasib 1sapanisertib 1sacituzumab govitecan 1ribociclib 1pertuzumab 1osimertinib 1lenvatinib 1fluciclovine F-18 1entrectinib 1elacestrant 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × sacituzumab govitecan × 30 days × Clear all
NCT04647916 2026-05-06

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

SWOG Cancer Research Network

Phase 2 Active not recruiting
44 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡